Table 4.
Clinical trials based on the use of CRISPR-Cas9 technology to provide more effective and universal CAR-T cell registered in ClinicalTrials.gov (June 2021)
| Condition | CAR | Target locus (knocked out) | Phase | Location | Participant number | NCT number |
|---|---|---|---|---|---|---|
| ALL | CD19 | MAP4K1 (HPK1) | 1 | China | 40 | NCT04037566 |
| NHL | CD19 | NA | 1 | USA | 50 | NCT04637763 |
| Solid tumor | Mesothelin |
PD-1 TRAC |
1 | China | 10 | NCT03545815 |
| BCL |
CD19 CD20 CD22 |
N.A | 1/2 | China | 80 | NCT03398967 |
| Solid tumor | Mesothelin | PD-1 | 1 | China | 10 | NCT03747965 |
| BCL | CD19 |
TRAC B2M |
1/2 | China | 80 | NCT03166878 |
Note: ALL acute lymphoblastic leukemia, BCL B cell lymphoma, TRAC T cell receptor alpha constant, B2M beta-2-microglobulin, PDCD1 or PD1 programmed cell death protein 1, NHL non-Hodgkin lymphoma, MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1, NA not available